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Sirtuins in Kidney Injury and Disease 
 





Acute kidney injury (AKI) is an extremely common medical affliction resulting from 
hypoxic, nephrotoxic and septic insults affecting approximately 20% of all hospital patients and 
up to 50% of patients in the intensive care unit. There are currently no therapeutics for patients 
that suffer AKI. Much recent work has focused on designing and implementing therapeutics for 
AKI. The sirtuins are a family of enzymes that play critical roles in regulating many cellular and 
biological functions. There are 7 mammalian sirtuins (Sirt1-7) that are known to regulate the 
acylation of a wide variety of pathways. Furthermore, all but one of the mammalian sirtuins have 
been shown to be important in mediating AKI based on preclinical studies. These diverse enzymes 
show exciting potential for therapeutic manipulation. While considerable research has been done 
on SIRT1 and its role in the kidney, much less is known about mitochondrial SIRT5 in the context 
of AKI. My research has strove to elucidate the role of SIRT5 in acute kidney injury through in 
vivo mouse studies and in vitro means with a particular focus on its function as a regulator of fatty 
acid oxidation. 
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1.0 Background and Significance 
1.1 Acute Kidney Injury 
Acute kidney injury (AKI) is a significant health care concern associated with high 
morbidity and mortality [1, 2]. Approximately 20% of hospitalized patients have AKI and 20- 60% 
of adult critically ill patients have AKI [3]. AKI is characterized by an abrupt decline of renal 
function, resulting in an inability to maintain electrolyte, acid-base, and fluid homeostasis [4]. AKI 
is a complex and multifactorial disease typically occurring as a mixed etiology of ischemia, 
nephrotoxicity, and sepsis. Many groups are working to identify the underlying mechanisms 
involved in AKI, including apoptosis, dysregulation of metabolism, autophagy, inflammation and 
the cell-cycle [5-9]. However, despite considerable improvements to our understanding of the 
pathophysiology of AKI, the exact mechanisms are still poorly understood, and no specific therapy 
exists. 
1.2 Pathogenesis of AKI 
Acute kidney injury is a complex and multifactorial disease. Although the exact 
pathogenesis of AKI depends on the cause of injury, the most common causes of AKI in patients 
is a mixed etiology of ischemia, nephrotoxicity, and sepsis. Despite potential differences in the 
initial injury, subsequent injury responses involve similar pathways and cell types. Among the 
molecular and cellular responses to injury are cell death of the tubular epithelial and endothelial 
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cells, innate and complement-mediated immune system activation, and impaired cellular 
metabolism. 
Models of ischemic and toxic injury to the kidneys shows a special susceptibility to injury 
of the renal tubular epithelial cells (RTEC). In all the complexity of AKI, it is generally accepted 
that the underlying basis of kidney injury is impaired energetics in the highly metabolically active 
nephron segments. The proximal tubular epithelial cells are especially sensitive to injury because 
they require more active transport mechanisms than other renal cell types. As such, they are heavily 
invested with mitochondria and peroxisomes to meet energy demands. When an injury or stress 
exceeds the mitochondria’s ability to sense and respond to changes in nutrient availability, 
apoptosis and necrosis are commonly initiated [10]. Several key enzymes and pathways are 
responsible for the efficient metabolism of resources in the kidney parenchyma. On the 
mitochondrial side, carnitine palmitoyletransferases (CptI and CptII) are critical enzymes essential 
for fatty acid oxidation. Apoptosis can activate intrinsically when the mitochondria fragments in 
response to decreased energy supply or when cytochrome c is released following outer 
mitochondrial membrane permeabilization [11]. Apoptosis of the tubular epithelial cells is further 
mediated by a network of factors including tumor suppressor protein p53, B-cell lymphoma 2 
(BCL2) family proteins, and caspases [12]. The consequences of such a tubular injury are many-
fold. Beyond the intrinsic cell death, various cytokines and chemokines are released from the 
damaged cells, triggering further cell death in adjacent cells and a robust immune response. 
Moreover, since the nephron’s natural function is to filter and reabsorb many substances from the 
tubular lumen, damage can result in toxic accumulation of these substances for surrounding 
epithelial cells, initiating a cascade of downstream molecular and cellular effects. 
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The endothelial cells of the renal microvasculature are tightly integrated with the nephron 
and play a critical role in the pathogenesis of AKI. Several studies have provided evidence 
supporting cross-talk between the endothelial cells and RTEC [13]. Unlike renal tubular epithelial 
cells, endothelial cells lack the capacity for regeneration following severe injury. Such injuries can 
interfere with normal vascular activity, influence coagulation cascades, and trigger inflammatory 
responses [14]. This reduction in blood flow and impaired metabolism can have injurious 
consequences for the interdependent tubular epithelial cells. 
An inflammatory response follows initial tubular and endothelial injury and amplifies 
injury to the RTEC and endothelial cells. Damaged endothelial cells upregulate a variety of 
adhesion molecules with leukocyte counterreptors that initiate an inflammatory cascade of 
cytokines, chemokines, and reaction oxygen species (ROS) when activated [15]. Inflammatory 
mediators are also released by the RTEC. RTEC produce interleukin (IL)-1, IL-6, IL-8, and 
transforming growth factor beta (TGF-B) while leukocytes produce IL-1, IL-8, ROS, and 
eicosanoids [16]. Both the innate and adaptive immune systems are involved in the pathogenesis 
of AKI and virtually every immune cell has been implicated in AKI [17-20]. Briefly, the early 
immune response consists of activation of dendritic cells and macrophages that produce cytokines 
and chemokines leading to an influx of leukocytes [21]. Dendritic cells activate cluster of 
differentiation 4 (CD4)+ natural killer T cells and promote inflammation [19]. Following initial 
injury, regulatory T cells and macrophages suppress ischemic injury or initiate repair of the injured 
tissue [22, 23]. The complement system is also prominent in several types of AKI and together 
with toll-like receptors (TLRs) acts as an early sensor of tissue injury. Blockade of complement 
activation prevents many of the downstream inflammatory manifestation of AKI [24]. 
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Peroxisome proliferator-activated receptors (PPARs) are important nuclear receptor 
proteins that regulate diverse cellular functions such as cell survival, lipid metabolism, and 
inflammatory response. All three types of PPARs (PPAR-α, PPAR-γ, and PPAR-β/δ) have shown 
protective roles in animal models of AKI [25-28] For example, PPAR-α-deficient mice are more 
susceptible to sepsis-associated AKI and have worse kidney function likely due to reduced fatty 
acid oxidation and increased inflammation [26]. Additional mechanisms of protection have been 
elucidated for PPAR-α in the context of kidney injury. Ischemic-AKI and cisplatin-AKI decrease 
expression and activity of multiple enzymes involved in fatty acid oxidation and glucose 
metabolism. Proximal tubule-specific overexpression of PPAR-α is sufficient to prevent loss of 
these enzymes and ameliorate kidney injury [29]. 
In summary, tubular cell death is a central feature of AKI and the pathogenesis of AKI is 
a complex interrelationship between the epithelial, endothelial, and immune cells. Following initial 
injury, these cells act in concert to promote inflammation in a positive feedback loop to exacerbate 
kidney injury. 
1.3 Sirtuins 
Sirtuins are a multi-dimensional group of genes that may provide insight into protective 
mechanisms during AKI. Sirtuins are a family of nucleotide adenine dinucleotide (NAD+)- 
dependent class III histone deacylases. The first identified sirtuin, Sir2, was found in budding yeast 
Saccharomyces cerevisiae and described as a regulator of transcriptional silencing of mating-type 
loci [30]. The discovery of Sir2’s dependence on NAD+ revealed a role for sirtuins as both energy 
sensors and as transcriptional effectors regulating the acetylation state of histones [31]. 
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Subsequently, many homologs of Sir2 have been discovered across all domains of life, establishing 
a highly conserved class of enzymes [32-34]. 
In mammals, there are seven sirtuins, SIRT1-7, which function to regulate metabolism and 
other diverse physiologic processes through direct enzymatic action on target proteins. Sirtuins act 
in different cellular compartments and exhibit broad enzymatic activity as deacetylases, mono-
ADP ribosyltransferases, demalonylases, deglutarylases, and desuccinylases [35-37]. Apart from 
the classic role as histone deacetylases, a diverse set of protein targets have also been identified in 
the cytoplasm and mitochondria [38]. Although sirtuins have notably been studied for their role in 
caloric restriction and the prevention of aging-related diseases such as cardiovascular disease and 
diabetes, their diverse substrates and role as sensors of cellular energy balance makes them a 
critical player to restoring cellular homeostasis following injury [39]. The kidney is one organ that 
is highly susceptible to age-related diseases, and sirtuins have been implicated in the 
pathophysiology of chronic and acute kidney diseases [40, 41]. 
1.4 Sirtuins in AKI 
1.4.1 Nuclear Sirtuins 
There are 3 nuclear sirtuins (SIRT1, 6 and 7) that have been shown to play key roles in 
AKI and these are discussed below. SIRT1 is the most studied sirtuin and is localized to the nucleus 
(Table 1). It was originally described as a histone deacetylase, but it was soon discovered that 
SIRT1 deacetylates other proteins [36, 42, 43]. Following DNA damage, SIRT1 deacetylates and 
represses p53 to reduce cell apoptosis and senescence [44, 45]. Similarly, SIRT1 regulates the 
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acetylation of the forkhead box type O (FOXO) transcription factors to attenuate FOXO-induced 
apoptosis and cell-cycle arrest [46]. SIRT1 also regulates both members of the peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha/estrogen- related receptor alpha (PGC-
1α/ERR-α) complex, essential metabolic transcription factors which control mitochondrial 
biogenesis and gluconeogenesis (Table 1) [47-49]. Apoptosis and mitochondrial dysfunction play 
a critical role in the pathogenesis of AKI. When an injury or stress exceeds the mitochondria’s 
ability to sense and respond to changes in nutrient availability, apoptosis is commonly initiated 
[10]. Apoptosis can activate intrinsically when the mitochondria fragments in response to 
decreased energy supply or when cytochrome c is released following outer mitochondrial 
membrane permeabilization [11]. Apoptosis of the tubular epithelial cells is further mediated by a 
network of factors including tumor suppressor protein p53, BCL2 family proteins, and caspases 
[12]. Given SIRT1’s strong role in regulating apoptosis, it is not  surprising there is a wealth of 
literature describing the renoprotective effects of SIRT1. In its renoprotective capacity SIRT1 was 
shown to protect against oxidative stress-induced apoptosis via deacetylation of FOXO3 in 
proximal tubular epithelial cells [50]. Further to this, in proximal tubular-specific SIRT1-
overexpressing mice, cisplatin-induced injury was attenuated by maintaining peroxisome number 
with concomitant upregulation of catalase and reduction of renal oxidative stress [51]. In another 
study, it was shown that SIRT1 activates PGC-1α,  resulting in renoprotection by activating 
mitochondrial biogenesis and improved respiration via oxidative phosphorylation [52]. Finally, 
SIRT1 also showed a protective effect by regulating apoptosis through deacetylating p53 and 
inhibiting p53-dependent transcription during cellular stress [53]. Thus, the mechanism of Sirt1 
protection is mediated by suppression of apoptosis likely downstream of metabolic signaling 
pathways. 
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SIRT6 is another sirtuin that localizes to the nucleus. It functions as both a deacetylase and 
ADP ribosyltransferase [54]. SIRT6 plays a significant role in genomic DNA stability and repair. 
Sirt6 knock-out mice present with severe progeria and typically only live for 3 months [55]. SIRT6 
deacetylates histone H3 at various lysine sites to maintain genome integrity and telomere function 
[56]. In response to DNA damage, it has been shown that SIRT6 promotes DNA end resection via 
deacetylation of C-terminal binding protein interacting protein (CtIP) [57]. In the context of the 
kidney, SIRT6 appears to be important for podocyte function and maintenance of glomerular 
function, as Sirt6 deletion in mice induces podocyte injury and decreased slit diaphragm protein 
expression [58]. Sirt6 overexpression in HK-2 cells (immortalized proximal tubular kidney cells) 
inhibits apoptosis induced by lipopolysaccharide and promotes autophagy while SIRT6 silencing 
promoted the secretion of cytokines tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) [59]. 
SIRT6 also deacetylates histone 3 to effectively inhibit ERK1/2 expression and reduce 
inflammation and apoptosis caused by cisplatin [60]. 
SIRT7 is a deacetylase uniquely localized to the nucleolus. Compared to other nuclear 
sirtuins, only a limited number of substrates have been identified. SIRT7 activates RNA 
polymerase I (RNA Pol I) by deacetylating upstream binding factor (UBF) [61]. Others have 
shown that SIRT7 regulates RNA Pol I transcription by deacetylating PAD53, a component of 
RNA Pol I [62]. Interestingly, lack of SIRT7 in mice shows protection against cisplatin-induced 
AKI. By regulating the nuclear expression of transcription factor nuclear factor kappa B (NF- κB), 
SIRT7 deficiency ameliorates cisplatin-induced AKI [63]. Regulation/dysregulation of NF-κB 
would have profound effects on the kidney response to AKI due to the role of the immune response 
during injury. Both the innate and adaptive immune systems are involved in the pathogenesis of 
AKI and virtually every immune cell has been implicated in AKI [17-20]. The protective 
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phenomena seen with SIRT7 deficient mice is perhaps due to SIRT7 deficiency reducing the 
expression of TNF-α, which normally enhances ROS production through the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase complex [63]. 
1.4.2 Mitochondrial Sirtuins 
There are 3 known mitochondrial sirtuins (SIRT3, 4 and 5). While SIRT3 is responsible 
for global protein deacetylation in mitochondria, SIRT4 exists as a mitochondrial ADP- 
ribosyltransferase and SIRT5 exhibit enzymatic activities as a deacetylase, desuccinylase, and 
demalonylase. The roles of SIRT3 and SIRT5 have been elucidated in kidney injury and are 
discussed below, while the role of SIRT4 is currently unknown in this context. 
As the major mitochondrial deacetylase, SIRT3 is responsible for the regulation of several 
metabolic enzymes and components of oxidative phosphorylation. SIRT3 deacetylates and 
activates mitochondrial acetyl-CoA synthetase (AceCS2), an enzyme involved in acetate 
utilization [64]. Similarly, SIRT3 has been shown to deacetylate long-chain acyl-CoA 
dehydrogenase (LCAD) to regulate fatty acid oxidation [65]. SIRT3 has also been demonstrated 
to deacetylate mitochondrial ribosome subunit MRPL10 to inhibit mitochondrial protein synthesis 
[66]. In addition, SIRT3 regulates various components of the electron chain, such as Complex II 
and ATP synthase, to enhance ATP levels [67, 68]. These studies reflect only part of SIRT3’s wide 
range of functions in mitochondrial ATP production, fatty acid oxidation, mitochondrial 
homeostasis, and ROS management. SIRT3 plays a significant role in the kidney, especially in 
the proximal and distal tubular compartments which contain abundant mitochondria. Several 
studies have described a renoprotective role for SIRT3 due to its role in maintaining mitochondrial 
dynamics and energy homeostasis. Indeed, Sirt3 knockout mice administered cisplatin have more 
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severe AKI and compromised mitochondrial dynamics [69]. SIRT3 overexpression in mice has 
the effect of promoting autophagy through regulation of the mechanistic target of 
rapamycinAMPK/mTOR pathway and protecting against a model of sepsis-AKI [70]. SIRT3 
overexpression promotes autophagy, upregulates p-AMPK and downregulates p-mTOR in cecal 
ligation and puncture mice, attenuating sepsis-induced AKI, tubular cell apoptosis, and 
inflammatory cytokine accumulation in the kidneys [71]. The blockage of autophagy induction 
largely abolished the protective effect of SIRT3 in sepsis- induced AKI. These findings indicate 
that SIRT3 protects against sepsis-induced AKI by inducing autophagy through regulation of the 
AMPK/mTOR pathway. SIRT3 also regulates FAO in mice by deacetylating liver kinase B1 and 
activating AMPK with the effect of reducing reactive oxygen species (ROS) and lipid peroxidation 
[72]. 
Most pertinent to this thesis is the mitochondrial SIRT5 was initially identified as a 
deacetylase targeting carbamoyl phosphate synthetase (CPS1) to regulate the urea cycle in liver 
[73]. However, it has since been discovered that SIRT5 functions as a demalonylase, deglutarylase, 
and desuccinylase rather than as a deacetylase [74]. SIRT5 has been shown to bind cardiolipin in 
the inner mitochondrial membrane and desuccinylate electron transport enzymes Complex I, 
Complex II, and ATP synthase [75]. SIRT5 desuccinylation targets identified via large-scale 
profiling studies suggest SIRT5 has a significant role in energy metabolism [76]. As a 
mitochondrial sirtuin, SIRT5 was expected to have a significant role in the kidney and in the 
maintenance of the kidney’s energy metabolism. However, few studies have investigated the role 
of SIRT5 in the kidney. The major focus of my research and this thesis comprises my research into 
the role of SIRT5 in kidney injury and disease. This research resulted in a publication for which I 
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was co-first author. The results will be elaborated in the “Results and Discussion” section of this 
thesis. 
1.5 Elucidating the Role of SIRT5 in Acute Kidney Injury 
Proximal tubule epithelial cells (PTEC) are highly sensitive to damage following AKI 
largely due to its high metabolic rate [77, 78]. To meet energy demands, PTEC rely on fatty acid 
β-oxidation (FAO). Parallel FAO pathways exist in mitochondria and in peroxisomes, both of 
which are notably abundant in PTEC. Mitochondrial FAO directly links to the mitochondrial 
electron transport chain and is an oxygen-intensive source of energy. Concomitant with oxygen 
utilization is the formation of reactive oxygen species (ROS) which are thought to be particularly 
damaging during ischemic- and cisplatin-induced AKI [79, 80]. Limiting mitochondrial FAO 
limits cardiac injury in the heart [81, 82] and in the kidney [25]. 
In contrast to mitochondria, little is known about the role of peroxisomes in the kidney, 
particularly in the context of AKI. Peroxisomes cannot produce energy. Rather, they metabolize 
long-chain fatty acids to acetate and other short-chain products, which, owing to their 
hydrophilicity, can cross membranes to either leave the cell or enter mitochondria where they may 
be oxidized to completion. Peroxisomes have been observed to physically interact with 
mitochondria and ablation of peroxisomal function has secondary effects on mitochondrial 
function [83]. Peroxisomes may serve as a sink for mitochondrially-produced ROS due to the 
abundance of catalase and other ROS-neutralizing enzymes in the peroxisome [84, 85]. 
Peroxisomes may also serve to protect PTEC from the accumulation of toxic long-chain fatty acids 
[86]. 
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Emerging evidence shows both FAO pathways are regulated by reversible post- 
translational modifications (PTM), in particular by lysine acylation and the sirtuin deacylase 
enzymes that remove these PTM [65, 87]. Sirt5, which is unique among the sirtuins in its substrate 
preference for succinyllysine, malonyllysine, and glutaryllysine [74, 88], also promotes 
mitochondrial FAO in liver and heart [76, 87]. Intriguingly, Sirt5 was recently shown to localize 
to peroxisomes. In direct contrast to its effect on mitochondrial FAO, Sirt5 was observed to 
suppress peroxisomal FAO in vitro and in rodent liver [89] The role of Sirt5 in the kidney has not 
yet been studied. Thus, we aimed to investigate the precise role of SIRT5 in AKI. 
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Figure 1: Sirtuins regulates different cellular and biologcal functions to impact kidney injury. SIRT3 and 
SIRT5 are mitochondrial sirtuins. SIRT3 maintains miotchondrial dynamics and energy homeostasis and 
promotes autophagy. SIRT5 is involved in fatty acid oxidation and energy metabolism. SIRT1, SIRT6, and 
SIRT7 are nuclear sirtuins. SIRT1 has a strong role in maintaining peroxisomes and mitochondria as well as 
in regulating apoptosis. SIRT6 is important for the maintenance of podocyte and glomerular function. SIRT7 
is involved in inflammation through regulation of NF-κB. SIRT2 is a cytoplasmic sirtuin and regulates both 
inflammation and apoptosis 
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2.0 Methods 
2.1 Ischemic- and cisplatin-AKI models in mice 
Homozygous global Sirtuin5 knockout mice (Sirt5-/-) [90] were obtained from the Jackson 
Laboratory (B6;129-Sirt5tm1Fwa/J, Stock #: 012757). B6/129S F2 strain wild-type (WT) mice 
were used as controls. Age-matched 10-14 weeks old male mice were used throughout the study. 
Ischemic-AKI was induced by a renal ischemia-reperfusion injury (IRI) model as previously 
descried [91] with modifications. Briefly, mice were anesthetized with inhalant 2% isoflurane. 
Core body temperature of the mice was monitored with a rectal thermometer probe and was 
maintained at 36.8-37.2°C throughout the procedures with a water heating circulation pump 
system (BrainTree Scientific, EZ-7150) and an infrared heat lamp (Shat-R-Shield). Buprenorphine 
(Par Pharmaceutical) was administered for pain control (0.1 mg/kg bw, s.c.). With aseptic 
techniques, a dorsal incision was made to expose the kidney. 22 minutes renal ischemia was 
induced by unilateral clamping of the left kidney pedicle with a non- traumatic microvascular 
clamp (Fine Science Tools, 18055-04). Renal reperfusion was visually verified. Delayed 
contralateral nephrectomy of the right kidney was performed at day 6 [92]. Mice were sacrificed 
at day 7 to harvest blood and the injured kidney. Serum was separated from the blood and analyzed 
by the Kansas State Veterinary Diagnostic Laboratory for levels of creatinine and blood urea 
nitrogen (BUN). 
To induce cisplatin-AKI, mice were given a single dose of 20mg/kg i.p cisplatin (Fresenius 
Kabi) or vehicle control of normal saline as described previously [93]. Mice were sacrificed on 
day 3 to harvest blood and the kidneys. 
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2.2 Cultured proximal tubular epithelial cells 
Primary mouse proximal tubular epithelial cells (PTEC) were isolated from single-cell 
kidney suspension of 10-14 weeks old, male, Sirt5-/-, B6/129 strain WT, or 129 strain WT mice 
by Dynabeads™ FlowComp™ Flexi Kit (Thermo Fisher Scientific) conjugated to Lotus 
Tetragonolobus Lectin (LTL) (Vector Laboratories, L-1320). Passage 3-6 PTEC were used for 
experiments. Human kidney proximal tubular epithelial cells (hPTEC) were obtained from ATCC 
(Manassass, VA). Both types of cells were cultured as previously described with modifications. 
Mouse primary PTEC were plated at 106 cells per well and, under serum-restricted 
conditions, (1) exposed to 24 hours of normoxia or hypoxia (FiO2 1%) in the hypoxia chamber 
(Coy Laboratory) or (2) treated with 24 hours 20µ M cisplatin or vehicle control of normal saline. 
Human proximal tubular cells (hPTEC) (ATCC PCS-400-010), were maintained in a 1:1 
mix of Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific) and Ham’s F12 (Thermo 
Scientific) containing 5mM glucose and supplemented with 2mM GlutaMAX (Thermo Scientific), 
1X Insulin-Transferrin-Selenium (Gibco), 36 ng/mL hydrocortisone, and 0.1% (v/v) 
penicillin/streptomycin at 37°C in 5% CO2. 
To knockdown Sirt5, the plasmid containing Sirt5 siRNA (Ambion, 16708) and the control 
plasmid (scrambled, Thermo Fisher Scientific, AM4611) were reverse-transfected into hPTEC by 
using INTERFERin transfection reagent (Polyplus, 409-10) according to the manufacturer’s 
protocol. hPTEC were used for experiments 48 hours after siRNA treatment. To inhibit ACOX1 
activity, 500nM 10,12-tricosadiynoic acid (TDYA, Sigma) is used [94]. 
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2.3 Combined Glucose/Oxygen Deprivation (CGOD)-mediated in vitro ischemic AKI 
hPTEC were subject to an in vitro ischemic-AKI model by combined glucose/oxygen 
deprivation (CGOD) insult. For the CGOD procedure, hPTEC in a 24-well or 96-well plates were 
exposed to 4 to 24 hours of normoxia or hypoxia (FiO2 1%) with defined glucose-free buffer (115 
mM NaCl, 1.0 mM NaH2PO4, 26.2 mM NaHCO3, 5.4 mM KCl, 1.8 mM CaCl2, 
and 0.8 mM MgSO4). After CGOD procedure, culture medium was replaced with glucose- 
containing buffer (+30mM glucose) and hPTEC moved to a regular incubator for normoxic 
treatment in the next 24 hours to simulate “reperfusion”. The defined glucose-free buffer was used 
instead of glucose-free cell culture media because other components in medium, such as amino 
acids, can alter the response of cells to hypoxia [95, 96]. 
2.4 Lactate Dehydrogenase release assay 
Cell death was assessed by lactate dehydrogenase (LDH) efflux using the LDH release 
assay kit (Promega) in accordance with the manufacturer’s protocol. Cytotoxicity was expressed 
as the ratio of the LDH release in the treated cell medium to that of the maximal LDH release. 
2.5 Western Blots 
Kidney lysates were lysed in radioimmunoprecipitation assay buffer (RIPA buffer; Thermo 
Fisher Scientific) and the homogenates plated in triplicate to measure protein concentration using 
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a Bradford assay kit (Bio-Rad). The following antibodies were used in this study; Anti-Acox1 
antibodies (1:1000, Rabbit, Abcam, ab59964), Pan-succinyllysine antibodies (1:1000, Rabbit, 
PTM Biolabs, PTM-401), Anti-Sirt5 antibodies (Rabbit, 1:50, Cell Signaling, 8782). Anti-
GAPDH or Anti-α/β-tubulin were used as loading controls at 1:100. 
2.6 Real-time PCR 
Real-time PCR analysis was performed as previously described [97], to determine mRNA 
level in whole kidneys. cDNA was reverse-transcribed from 500 ng of total RNA with SuperScript 
First-Strand Synthesis System (Thermo Fisher Scientific). Real-time PCR analysis was performed 
with gene specific primer oligos, SsoAdvanced™ SYBR® Green Supermix (Bio- Rad), and 
CFX96 Touch™ Real-Time PCR Detection System with C1000 Thermal Cycler (Bio- Rad). 
Cycling conditions were 95 °C for 10 minutes, then 40 cycles of 95 °C for 15 seconds and 60 °C 
for 1 minute. Rn18S was used for endogenous control. Expression was compared to Rn18S 
endogenous control and analyzed using the 2 -∆∆Ct method. 
2.7 Tissue section analysis 
Kidneys were fixed in 4% paraformaldehyde and embed in paraffin. These tissues were 
sectioned at 4 microns. The kidney sections were stained with hematoxylin and eosin (H&E) or 
Masson’s Trichrome. H&E stained slides were subject to histological evaluation. 40x images of 
renal cortex and medulla were obtained with a Leica DM2500 optical microscope. Semi-
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quantitative scoring (0-4) for tubular injury was performed in terms of tubular dilation, 
proteinaceous cast formation, and loss of brush border. To quantify Masson’s trichrome stained, 
collagen-rich area, tiling imaging system via TissueFAXS PLUS (TissueGnostics) were used to 
capture the entire kidney section with 20x objectives. Masson’s Trichrome positive area was 
quantified with NIS Elements software (Nikon). All tissue evaluation was performed in a blinded 
fashion. 
Immunostaining was performed as previously described with paraffin-embedded tissues 
and with following primary antibodies or lectins: -galactosidase (chicken, 1:200, Abcam, 
ab9361), Endomucin (rat, 1:200, Santa Cruz, sc-65495), Kim1 (rat, 1:100, R&D Systems, 
MAB1817), NCC (Rabbit, 1:250, Millipore, AB3553), NGAL (rat, 1:50, abcam, ab70287), 
PMP70 (Rabbit, 1:200, Abcam, ab85550), Dolichos Biflorus Agglutinin (DBA) (1:200, Vector 
Laboratories, FL-1031), or LTL (1:200, Vector Laboratories, FL-1321). 
2.8 Palmitate oxidation assay 
14C-palmitate (PerkinElmer) was conjugated to BSA and used at 125 M in 200µl reactions 
as described [65]. 14CO2 was captured on filter papers soaked in 1M KOH and water- soluble 14C-
labeled FAO products were separated by the method of Bligh and Dyer [98] and subjected to 
scintillation counting. Peroxisomal FAO was defined as the rate of palmitate oxidation in the 
presence of the irreversible mitochondrial FAO inhibitor etomoxir (100 µM). Data were 
normalized to protein concentration.  
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2.9 Oroboros high-resolution respirometry 
Freshly-prepared kidney homogenates were analyzed with an Oroboros Oxygraph-2K 
using our previously published method [99]. Complex I respiration was defined as 
malate/pyruvate/glutamate-driven oxygen consumption in the presence of ADP, while Complex II 
respiration was defined as succinate-driven oxygen consumption. 
2.10 Quantitative mass spectrometry 
Both 7-day renal IRI- and contralateral control- kidney tissues (n=3) were homogenized, 
trypsinized, and then succinylated peptides were enriched using the PTMScan Succinyl-Lysine 
Motif Kit (Cell Signaling Technologies). Following reverse-phase HPLC-ESI-MS/MS, succinyl 
enriched samples were analyzed by dataindependent acquisition (DIA, e.g. SWATH) on a 
TripleTOF 6600, and site-specific changes in succinylation were quantified using Skyline as 
described [100-102]. 
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3.0 Results and Discussion 
3.1 Sirt5-/- kidneys exhibit protein lysine hyper-succinylation 
Sirt5 is highly expressed in kidney [73] but its role in kidney function has not been 
examined. I confirmed that global Sirt5 knockout mice (Sirt5-/-) have no detectable Sirt5 mRNA 
in the kidney (Fig 2A). Similar to liver and heart, Sirt5 deletion in the kidney leads to accumulation 
of post translation modification (PTM) known as lysine succinylation shown by a pan anti-
succinyllysine western-blotting for whole kidney lysates (Fig 2B). The mutant allele in Sirt5-/- 
mice bears a lacZ reporter cassette [90] . β-galactosidase (β-gal) immunostaining revealed that 
Sirt5-β-gal is co-localized in Lotus tetragonobolus lectin (LTL)-positive PTEC (Fig 2C), in 
Thiazide-Sensitive NaCl Cotransporter (NCC)-positive distal tubular epithelial cells and Dolichos 
Biflorus aggluttanin (DBA)- positive collecting ducts but was absent from Endomucin- positive 
microvasculature (Not shown). In wild-type (WT) mice, Sirt5 mRNA was expressed in the whole 
kidneys and was enriched in isolated primary PTEC (Fig 2D). At baseline, Sirt5-/- kidneys appear 
histologically (Fig 2E, F) and functionally normal with unaltered serum creatinine and blood urea 
nitrogen (BUN) compared to WT (Fig. 2F). 
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Figure 2: Sirt5-/- kidneys exhibit protein lysine hyper-succinylation but normal morphology and function. 
Real-time PCR of Sirt5-/- kidney confirms no detectable Sirt5 mRNA in mouse kidney (n=4/group). B. Western-
blotting of kidney lysates (50 µg) with anti-succinyllysine antibody was used to assess succinylation levels in 
mouse kidneys derived from wild-type (WT) or Sirt5-/- mice (n=4/group). C. The Sirt5-/- mutant allele contains 
a lacZ cassette that allows for the interrogation of expression using an anti-β-galactosidase (β- gal) antibody 
(Sirt5-β-gal, red). Abundant expression of Sirt5 is co-localized in the proximal tubular epithelial cells (LTL, 
green). Scale bar = 25µm. D. Real-time PCR of whole kidney compared with isolated LTL+ proximal tubular 
epithelial cells (PTEC) suggest that Sirt5 expression is enriched in PTEC (n=3/group). E-F. H&Estained 
kidneys of wild-type (WT) and Sirt5-/- kidneys at baseline. No discernable differences were noted between WT 
and Sirt5-/- kidneys. Scale bar = 200µm. G, H. Serum levels of (G) BUN and (H) creatinine were not 
significantly different at baseline between WT and Sirt5-/- mice (n=4/group). All data are presented as dot plots 
plus mean ± SEM. t-test 
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3.2 Sirt5-/- kidneys are protected against ischemic-AKI in mice 
To test the role of Sirt5 in ischemic-AKI, Sirt5-/- mice were subjected to a renal ischemia-
reperfusion (IR) mediated ischemic-AKI model and were sacrificed 7 days later. H&E- stained 
histopathology revealed decreased proteinaceous casts, less severe tubular dilation, and reduced 
loss of brush border in Sirt5-/- kidneys (Fig 3A, D, G). Kidney injury molecule-1 (Kim- 1), which 
localizes to injured PTEC [103], was much more prominent in WT kidney (Fig 3B versus 3E). 
Further, neutrophil gelatinase-associated lipocalin (NGAL), another marker for kidney tubular 
injury[104], was observed in many WT but was virtually absent in Sirt5-/- PTEC (Fig 3C, C’ 
versus F, F’). Real-time PCR for Lcn2 (NGAL mRNA) confirmed its decreased mRNA level in 
Sirt5-/- kidney (Fig 3J). Finally, kidney function was protected in Sirt5-/- mice as evidenced by 
reduced serum creatinine and BUN (Fig. 3H, I). Interestingly, similar results were observed by 
using the heterozygous mutant (Sirt5+/-) and their littermate WT controls, suggesting that half of 
Sirt5 gene dosage is sufficient to protect against ischemic-AKI. 
PTEC are sensitive to ischemic- and cisplatin-AKI, and are reliant upon mitochondria for 
energy metabolism; Sirt5 is known to regulate mitochondrial function and is enriched in PTEC 
(Fig 2). Therefore, I hypothesized that the protection against ischemic-AKI in Sirt5-/- was 
occurring within PTEC. To test this, primary PTEC were isolated from Sirt5-/- and B6/129-strain 
WT mice and exposed to 24-h, 1% hypoxic insult in vitro. Following the hypoxia exposure, 
expression of the tubular injury markers, Havcr1 (Kim-1 mRNA), Lcn2, and Interleukin-18 (IL- 
18) was significantly reduced in Sirt5-/- PTEC (Fig 4A). Sirt5-/- mice are a mixed 
background of the C57Bl/6 and 129Sv strains, and 129Sv-strain mice have been shown to exhibit 
resistance to ischemic-AKI [105]. To determine if this is the case in cultured mouse PTEC, I 
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subjected PTEC from WT B6/129, WT 129, and Sirt5-/- mice to 24 h of 1% hypoxia. The results 
confirm that  (1) 
WT 129 is more protective than WT B6/129, evidenced by reduction of Havcr1 and Lcn2 
mRNA and that (2) Sirt5-/- is more protective than WT 129, shown by reduction of Havcr-1, IL-
18, and Lcn2 mRNA (Not shown). I further modeled ischemic-AKI in vitro with primary human 
PTEC (hPTEC) using a combined glucose/oxygen deprivation (CGOD) protocol [106]. In this 
protocol, glucose and oxygen are deprived for the first 24-h and then added back to “reperfuse” 
for an additional 24-h. A siRNA knockdowns Sirt5 levels, with an efficiency of ~80%, when 
compared to a scrambled siRNA control (Fig 4C). At the end of the 24-h CGOD and the subsequent 
24-h “reperfusion” period, hPTEC with Sirt5 knockdown demonstrated protection as evidenced 




Figure 3: Sirt5-/- kidneys are protected against ischemic-AKI at 7 days following injury. A, D, G. 
H&Estained kidneys of (A) wild-type (WT) and (D) Sirt5-/- kidneys that were subjected to the ischemic-AKI 
model. The Sirt5-/- kidneys had decreased injury score as compared to WT kidneys, evidenced by 
proteinaceous casts in WT (arrow heads), dilated tubular structures, and vacuolization (arrows) that were 
decreased in Sirt5-/- kidneys (n=5-8/group) Scale bar = 100µm. B and E. Immunostaining for kidney injury 
molecule 1 (Kim1, red) in the proximal tubular epithelial cells (PTEC) (LTL, green) showed a large increase 
in the amount of Kim1 expression in the (B) WT compared to very low levels in the (E) Sirt5-/- PTEC. Scale 
bar = 100µm. C,C’(inset) and F,F’(inset). Immunostaining for neutrophil gelatinase-associated lipocalin 
(NGAL, red) in PTEC (LTL) was observed in many WT while virtually absent from Sirt5-/- PTEC. Scale bar 
= 50µm. J. Real-time PCR for Lcn2 (NGAL mRNA) confirms the decrease of Lcn2 in Sirt5-/- kidneys 
compared to WT (n=5-7). H and I. Serum levels of (I) Creatinine and (J) BUN are decreased in the Sirt5-/- 
mice compared to WT, suggesting protected kidney function in the Sirt5-/- mice (n=11-14/group). All data are 
presented as dot plots plus mean ± SEM. *p<0.05, ****p<0.0001, t-test 
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Figure 4: Loss-of-function of Sirt5 in proximal tubular epithelial cells is protective against injury in vitro. A. 
24-h 1% hypoxia-exposed primary proximal tubular epithelial cells (PTEC) derived from Sirt5-/- kidneys 
exhibited reduced mRNA levels of injury markers Havcr1 (Kim1 mRNA), Lcn2 (NGAL mRNA), and IL18, 
compared to B6/129-strain wild-type (WT) PTEC (n=3/group). B. 24-h Cisplatin-treated primary mouse 
PTEC from Sirt5-/- kidneys exhibited reduced mRNA levels of Lcn2, compared to WT PTEC (n=3/group). C. 
Western blotting confirms siRNA knockdown (KD) of Sirt5 in primary human PTEC (hPTEC). D. hPTEC is 
subjected to combined glucose/oxygen deprivation (CGOD)-mediated in vitro ischemic-AKI model; E. Sirt5 
KD hPTEC showed a marked decrease in lactate dehydrogenase (LDH) release (n=3/group). All data are 




3.3 Sirt5-/- mice are protected against cisplatin-induced AKI 
To determine if the protection afforded by Sirt5 loss-of-function extends to other forms  of 
AKI, Sirt5-/- mice were challenged with a high dose (20 mg/kg bw i.p) of the nephrotoxin cisplatin 
and were sacrificed 3 days later. Cisplatin specifically targets PTEC. H&E-stained kidney tissues 
demonstrated less severe tubular injury in cisplatin-treated Sirt5-/- mice compared to WT mice 
(Fig 5A-C). Kidney function was also protected in Sirt5-/- mice as evidenced by reduced serum 
creatinine and BUN (Fig 5D, E). During the 72-h post cisplatin treatment, WT mice lost 14.5% of 
their body weight compared to just 8.4% among Sirt5-/- mice (Fig 5F), suggestive of a blunted 
response to cisplatin in the Sirt5-/- mice. Real-time PCR analysis for Havcr1 and Lcn2 confirmed 
decreased mRNA level of the tubular injury markers in Sirt5-/- kidney (Fig 5G). Consistent with 
this, many WT PTEC were co-localized with NGAL while this was not observed in Sirt5-/- PTEC 
(Fig 5H-I). Renoprotection was also confirmed in the PTEC as evidenced by the strong expression 
of Lcn2 in WT primary PTEC treated with 20 µM cisplatin in vitro as compared to Sirt5-/- PTEC 
(Fig 5B). Finally, cultured primary PTEC derived from heterozygous Sirt5+/- mice reduced 
mRNA level of Lcn2 after 24-h cisplatin treatment when compared to the PTEC derived from their 
littermate WT controls (Not shown). 
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Figure 5: Sirt5-/- kidneys are protected against cisplatin-induced AKI at 3 days following injury. A-C. H&E- 
stained kidneys of (A) wild-type (WT) and (B) Sirt5-/- kidneys that were subjected to the cisplatin-AKI 
model. The Sirt5-/- kidneys had decreased injury kidneys compared to WT (n=4-8). Mann–Whitney U test. 
H-J. WT and Sirt5-/- kidneys were immunostained for NGAL (red) and proximal tubular epithelial cells 
(PTEC) (LTL, green). WT kidneys (H-H’) had increased NGAL positive (arrows, red) in LTL-positive PTEC 
than Sirt5-/- kidneys (I). Scale bar = 50µm. All data are presented as dot plots plus mean ± SEM. *p<0.05, 
**p<0.01, ****p<0.0001 
27 
3.4 Total FAO is increased in Sirt5-/- kidneys both at baseline and after ischemic-AKI 
A lysine succinylome analysis implicated FAO as a key pathway to confer renoprotection 
in Sirt5-/- kidneys. This pathway is known to be suppressed in Sirt5-/- liver and heart [87, 107]. 
To explore the effects of Sirt5 loss-of-function on kidney FAO, I followed the catabolism of 14C-
labeled palmitate to 14CO2 in fresh kidney lysates prepared from uninjured kidneys. Contrary to 
expectation, baseline FAO rates were significantly elevated in Sirt5-/- kidneys (Fig 6A). This was 
not due to a greater number of mitochondria, as quantification of the Tomm20- positive 
mitochondria (Fig 6B) and the mitochondrial: nuclear DNA ratio (Fig 6C) indicated similar 
mitochondrial abundance across genotypes. Consistently, baseline FAO rates were trending to be 
increased (p=0.10) in cultured Sirt5-/- PTEC (Not shown). Our group also analyzed respiratory 
chain function, previously shown to be impaired in Sirt5-/- liver mitochondria [99], in kidney 
lysates using an Oroboros high-resolution respirometer. As in liver, uninjured Sirt5-/- kidney 
mitochondria demonstrated a significant decrease in respiration on the Complex II substrate 
succinate (Fig 6D, E). 
I next repeated the same set of experiments on Sirt5-/- and WT kidney tissue isolated Day 
7 postrenal IRI. FAO rates, overall, were an order of magnitude lower in kidneys subjected to 22-
min renal IRI compared to baseline (compare Fig 6F to 6A). A more severe 30-min renal IRI 
reduced FAO rates even further. 
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Figure 6: Fatty acid oxidation (FAO) is enhanced in Sirt5-/- kidneys. A. Total FAO is increased at baseline in 
whole kidney homogenates of Sirt5-/- mice compared with wild-type (WT), as measured by 14C-palmitate 
oxidation. (n=3/group) B. Immunostaining reveals equivalent numbers of Tomm 20 positive mitochondria 
(red) in WT and Sirt5-/- proximal tubular epithelial cells (PTEC) (LTL, green) at baseline. Scale bar = 50µm. 
C. Mitochondrial DNA (mtDNA) measured by real-time PCR was found to be equivalent between control and 
Sirt5-/- kidneys (n=3-4/group). D-E. Baseline respirometry revealed that complex II specifically and not 
complex I of the electron transport chain was reduced in Sirt5-/- kidneys compared with WT (n=6-7/group). 
F-G. After a moderate (22-min) (F) or severe (30-min) (G) renal ischemia reperfusion injury (IRI), Sirt5-/- 
kidneys displayed an increased rate of FAO (n=3-4/group) H. After renal-IRI mitochondria (Tomm 20, red) 
appear to be present in both WT and Sirt5-/- proximal tubules (LTL, green). Scale bar = 50µm. I. 
Mitochondrial DNA trended to be increased in Sirt5-/- kidneys compared with WT. (n=3/group) J. No  
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difference was observed in complex I or Complex II utilization of the electron transport chain after renal-IRI. 
(n=3/group). All data are presented as dot plots plus mean  ± SEM. *p<0.05, t-test 
3.5 Increased FAO in Sirt5-/- kidneys is localized to peroxisomes 
There are two parallel pathways of FAO, one in mitochondria that directly transmits 
reducing equivalents into the electron transport chain and acetyl-CoA into the TCA cycle, and one 
in peroxisomes that partially chain-shortens long-chain fatty acids and releases short-chain 
products into the cytosol. These short-chain products can either be taken up by mitochondria and 
metabolized to completion or released from the cell. PTEC contain an abundance of peroxisomes 
and increased peroxisomal function has been previously linked to renoprotection [108, 109]. 
Recently, peroxisomal gain-of-function was reported in Sirt5-/- cell lines and mouse liver [87, 99, 
110]. I therefore interrogated Sirt5-/- kidneys for peroxisomal FAO at baseline and following renal 
IRI. The catabolism of 14C-palmitate was followed to 14CO2 and water-soluble (short- chain) 
products in kidney homogenates in the presence of etomoxir, an irreversible inhibitor of 
mitochondrial FAO. Etomoxir-resistant FAO is ascribed to peroxisomes [25] . Sirt5-/- kidney 
homogenates at baseline displayed a significantly higher rate of peroxisomal FAO than WT kidney 
homogenates (Fig 7A). A similar result was obtained using freshly isolated primary mouse PTEC 
(Fig 7B) and a similar trend was observed using cultured hPTEC with Sirt5 siRNA knockdown 
(Not shown). After a severe 30-min renal IRI, peroxisomal FAO was 7-fold higher in Sirt5-/- 
kidney homogenates (Fig 7C). The 30-min renal IRI homogenates were western- blotted for acyl-
CoA oxidase-1 (ACOX1), the rate-limiting enzyme of peroxisomal FAO. The abundance of 
ACOX1 was significantly higher in Sirt5-/- kidney (Fig 7D). Sirt5-/- kidneys were confirmed to 
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have greater abundance of Peroxisomal Membrane Protein 70 (Pmp70)-positive peroxisomes in 
baseline and post-renal IRI tissues (Fig 7E, F). To test whether inhibition of peroxisomal FAO 
abrogated the beneficial effect of Sirt5 inhibition, we used Sirt5 siRNA in cultured human PTEC 
± 10,12-tricosadiynoic acid (TDYA), an irreversible peroxisomal FAO inhibitor, during in vitro 
ischemic-AKI (Fig 7G). The combined Sirt5/peroxisomal FAO inhibition removed the protective 
role of Sirt5 knockdown confirming the role of peroxisomal FAO switching in driving the PTEC 





Figure 7: Increased FAO by Sirt5 loss-of-function is localized to peroxisomes. A-C. Etomoxir-insensitive 14C- 
palmitate oxidation, which represents peroxisomal FAO, was measured in kidney homogenates at baseline 
(n=3/group) (A), in freshly isolated proximal tubular epithelial cells (PTEC) (n=3/group) (B), or after 30- 
minute renal-IRI (n=3/group) (C). t-test D. Western blot analysis showed an upregulation of the rate-limiting 
peroxisomal FAO enzyme ACOX1 in Sirt5-/- kidney homogenates. Mann–Whitney U test. E-F. PMP70 (red) 
is a peroxisome marker, LTL (green) is a marker for PTEC and DAPI (blue). E=baseline, F=post renal IRI. 
(n=4/group) E and F. At baseline (E) there appear to be more peroxisomes present in the proximal tubules 
(arrows) and this persists after injury. Scale bar = 50µm. (F). G. Human PTEC (hPTEC) was treated ± Sirt5 
siRNA and ± TDYA (ACOX1 inhibitor) during combined glucose/oxygen deprivation (CGOD)-mediated in 
vitro ischemic-AKI and was evaluated its effect by LDH release (cell death marker). TDYA treatment 
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abrogates the protective effect by Sirt5 siRNA. (n=3/group). Tukey comparison. All data are presented as dot 
plots plus mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 
3.6 Pharmacological agents to modulate metabolism and AKI in vitro 
Given the finding that deletion of SIRT5 is renoprotective, another therapeutic avenue 
exists for selective sirtuin inhibitors. In the case of SIRT5, which uniquely targets succinyl 
modifications, inhibitors targeting the succinyl substrate are current under development [111, 112]. 
However, the development of sirtuin inhibitors holds some risk as sirtuins are involved in myriad 
pathways, and whether modulating sirtuins will have a beneficial or deleterious effect in humans 
is unclear. The compromise to this double-edged sword might be the development of therapeutics 
targeting the pathways shown to be regulated by sirtuins rather than the sirtuins themselves. To 
that end, I tested the therapeutic efficacy of various metabolic modulators in vitro for their effect 
on cell injury using a lactate dehydrogenase (LDH) release assay (Figures 8-11). Although 
Etomoxir, an irreversible inhibitor of Cpt1, has been shown to protect against kidney injury. 
Teglicar, a reversible inhibitor of Cpt1, accelerated release of LDH and exacerbated injury (Figure 
8). Addition of pharmacological agent C75, a fatty acid synthase inhibitor, also exacerbated injury 
especially 12 hours after treatment (Figure 9). R-aminocarnitine, an inhibitor of Cpt2 (while not 
acting as a PPAR-activator), had only slightly elevated release of LDH compared to DMSO control 
(Figure 10). Finally, bezafibrate, a PPARα activator, showed a modest reduction in LDH release 







Figure 8: Effect of various metabolic modulators on the release of lactate dehydrogenease in hRPREC cells. 
A. hPTEC showed a marked increase in lactate dehydrogenase (LDH) release compared to DMSO control 
when given Teglicar, an irreversivle inhibitor of Cpt1 (n=3/group). B. hPTEC showed a sharp increase in 
lactate dehydrogenase (LDH) release compared to DMSO control when given C75, an inhibitor of fatty acid 
synthase. C. hPTEC showed a moedest increase in lactate dehydrogenase (LDH) release compared to DMSO 
control when given R-aminocarnitine, an inhibitor of Cpt2 (n=3/group). D. hPTEC showed a modest decrease 
in lactate dehydrogenase (LDH) release compared to DMSO control when given bezafibrate, a PPARα 
activator (n=3/group). 
3.7 Discussion 
My studies interrogated the role of Sirt5 during AKI and found that loss-of-function of 
Sirt5 was renoprotective. This finding is opposite to those observed for Sirt1 and Sirt3, for which 
deletion exacerbates AKI [69, 113]. We propose that the beneficial nature of Sirt5 loss-of- function 
stems from the unique combination of only a minor loss of mitochondrial function combined with 
a significant peroxisomal gain-of-function. Deletion of Sirt5 in the kidney caused only a modest 
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reduction in mitochondrial function at baseline, i.e. ~10% loss of succinate- induced respiration 
and a suppression of mitochondrial FAO, and following injury, mitochondrial respiratory chain 
function was the same across genotypes. This could be due to the clear accumulation of protein 
succinylation in WT mitochondria following injury (731 succinylated peptides versus 489 at 
baseline), such that more than 50 peptides exhibited significantly higher succinylation in WT 
kidney compared to Sirt5-/- kidney after renal IRI (Not shown). Protein succinylation in 
mitochondria is determined by the concentration of succinyl- CoA, which chemically reacts with 
lysine residues on the surface of proteins, and the countering activity of Sirt5 [114]. I speculate 
that WT kidneys rely more upon mitochondria during AKI than Sirt5-/- kidneys, causing 
accumulation of succinyl-CoA and therefore greater protein succinylation, effectively closing the 
gap in mitochondrial function between WT and Sirt5-/- kidneys. Peroxisomal function, in contrast, 
remains enhanced in Sirt5-/- kidney following injury. Increased peroxisomal function has 
previously been linked to renoprotection in mice treated with etomoxir, in transgenic mice 
overexpressing Sirt1 in the kidney, and in animals treated with fibrates, a class of drugs that 
promotes peroxisomal proliferation [115] . PTEC is the major site of injury during several forms 
of AKI, and is rivaled only by the liver in terms of peroxisome abundance [116]. As previously 
reported for liver [110] we observed a peroxisomal gain-of function, at least for the FAO 
pathway, in Sirt5-/- kidneys. Peroxisomes are also known to play an important role in the brain 
[117]. Interestingly, Sirt5-/- mice are protected from ischemic stroke [118], while in the heart Sirt5 
deletion exacerbates ischemic injury [119]. The heart contains only “micro-peroxisomes” which 
are not thought to contribute significantly to FAO. I speculate that the capacity for peroxisomal 
FAO might explain why the kidney and brain, but not the heart, are privy to the protective effects 
of Sirt5 deficiency. Also, defective FAO in PTEC is responsible for interstitial fibrosis. We showed 
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that although mRNA for two fibrosis markers are decreased in Sirt5-/- kidneys, no discernable 
difference was observed in tissue across genotypes. 
3.7.1 Future Directions 
Future studies will evaluate whether Sirt5 loss-of-function leads to fibrosis at later time 
points (28-42 days post AKI) with more severe ischemic insult, known to drive fibrosis [120]. 
Therapeutically, due to the deleterious effect on the heart, inhibition of Sirt5 would need to be 
localized to the kidney. Recent advances have been made in targeting drug delivery to the kidney 
[121, 122]. Although our data in the Sirt5 heterozygous mice is therapeutically promising as a half 
gene dosage is sufficient to elicit protection and would likely not lead to off target effects. Further, 
due to the unique substrate specificity of Sirt5, several Sirt5-specific inhibitors have been 
developed which demonstrate in vitro efficacy [111, 112]. Future experiments should also 
endeavor to delete the Sirt5 gene and FAO specifically in the proximal tubular compartment and 
other nephron segments to determine if the renoprotective phenomena stems from the proximal 
tubular or other nephron compartments. Additional pharmacological inhibition/stimulation 
targeting relevant metabolic pathways implicated in these studies should also be performed to 
determine the relative importance of these various pathways to the renoprotection observed herein. 
3.7.2 Conclusion 
In conclusion, our results demonstrated that Sirt5 loss-of-function ameliorated ischemic- 
and cisplatin AKI in mice and human due to a switch away from mitochondrial FAO towards 
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peroxisomal FAO. Our findings uncover an attractive and novel candidate pathway modulated  by 
Sirt5 for the treatment of AKI. 
The study of sirtuins in the kidney has led to impressive advances in our understanding of 
sirtuin targets involved in renoprotection and in the development of a number of different 
pharmacological interventions that are effective in ameliorating injury in animal models of AKI. 
However, the promise of these developments is generally tempered by the results of clinical  trials 
in patients with AKI. Therapies effective in animal models of AKI have translated to little or no 
effectiveness in humans. However, this failing might stem from deficiencies in preclinical models 
of AKI and an ability to design the clinical trial itself [123]. Although many auspicious sirtuin 
targets have been identified, the failure to effectively translate animal data to an effective human 
intervention highlights the importance of studying AKI in multiple model systems. In addition to 
the multiple in vivo models of AKI available, including the ischemia-reperfusion model, cisplatin-
induced AKI, and sepsis-associated AKI, multiple in vitro models are used to study AKI [124, 
125]. The mechanistic differences between these various models adds to the complexity of AKI 
pathogenesis and elucidating the role that sirtuins play in each model will further understanding 
and therapeutic application of the sirtuins. 
My studies of Sirt5 in mice and in vitro have implicated various metabolic pathways 
(particularly FAO) and the use of various pharmacological modulators of these same pathways is 
an auspicious future direction for the development of an AKI therapeutic. 
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